Abstract Number: 1264 • ACR/ARHP Annual Meeting 2018
Modeling the Costs and Outcomes Associated with Treatment Sequences, with and without Tofacitinib, for Moderately to Severely Active Psoriatic Arthritis in the US
Background/Purpose: Psoriatic Arthritis (PsA) is a chronic progressive inflammatory condition associated with significant direct and indirect costs. Tofacitinib is an oral Janus kinase inhibitor for…Abstract Number: 335 • ACR/ARHP Annual Meeting 2013
Comparing Adalimumab and Etanercept As First Line Agents In Patients With Psoriatic Arthritis. Data From The Rhumadata® Clinical Database and Registry
Background/Purpose: No long term head-to-head comparative studies of anti-TNF agents in psoriatic arthritis have been published. Controversy exists over the selection of initial biologic therapy…Abstract Number: 1840 • ACR/ARHP Annual Meeting 2012
Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated On Non-Biologic Disease-Modifying Anti-Rheumatic Drugs
Background/Purpose: Several treatment options are available for psoriatic arthritis (PsA) patients (pts). Oral disease modifying anti-rheumatic drugs (DMARDs) are often used as a first-line treatment…
ACR Meeting Abstracts